tumor necrosis factor receptor type i, p55 soluble fragment
Recombinant proteinexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00090129)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
- Tumor necrosis factor receptor R1INHIBITOR
TNFRSF1A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107911 ↗
Also known as
- glycoprotein tnf-bp (tumor necrosis factor-binding protein) (human disulfide variant 1)
- onercept
- onercept
- onercept
- peg-linked dimeric form of rstnf-ri
- peg-linked dimeric type i soluble receptor of tnf
- peg-(rstnf-ri)2
- receptor(55), tnf
- recombinant human soluble p55 tumour necrosis factor receptor
- recombinant human tumor necrosis factor-binding protein-1
- r-htbp-1
- r-htbp-1
- tnf receptor p55
- tnfrp55
- tnf-sr55
- tumor necrosis factor receptor 55
- tumor necrosis factor receptor type i, p55 soluble fragment
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00090129 | Phase 3 | Sep 1, 2004 | Merck Serono |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck Serono | For profit | 1 | 1 | 1 | 2004 |
1 organizations
Page 1 / 1